摘要
目的观察散血明目片联合雷珠单抗眼内注射治疗湿性年龄相关性黄斑变性(AMD)的疗效。方法将77例(77眼)湿性AMD患者,采用随机原则分为联合治疗组(39眼)和雷珠单抗组(38眼)。联合治疗组:散血明目片口服+雷珠单抗眼内注射;雷珠单抗组:雷珠单抗眼内注射。眼内注射每月1次,连续3次;散血明目片连续口服3月。通过最佳矫正视力,光学相干断层扫描(OCT)及眼底荧光血管造影(FFA)检查,分析治疗前后最佳矫正视力、黄斑视网膜厚度及视网膜渗漏的变化。结果治疗后3个月最佳矫正视力联合治疗组(0.09±0.05 vs 0.38±0.14)、雷珠单抗组(0.08±0.04 vs 0.29±0.15)均有提高,治疗前后差异及治疗后组间差异均有统计学意义(P<0.01或P<0.05)。治疗后3个月黄斑视网膜厚度联合治疗组[(315.44±21.99)μm vs(237.13±27.14)μm]、雷珠单抗组[(317.33±21.63)μm vs(254.56±26.32)μm]均有减少,治疗前后差异及治疗后组间差异均有统计学意义(P<0.01或P<0.05)。联合治疗组有28眼渗漏消失,7眼渗漏面积明显缩小,4眼渗漏面积无明显变化;雷珠单抗组24眼渗漏消失,3眼渗漏面积明显缩小,11眼渗漏面积无明显变化,治疗后3个月组间渗漏总改善率差异有统计学意义(P<0.05)。结论散血明目片联合眼内注射雷珠单抗治疗湿性AMD可提高视力,减轻黄斑水肿,使视网膜渗漏减轻,是治疗湿性AMD的有效方法。
Objective To evaluate the clinical curative effect of Sanxue Mingmu tablets combined with intravitreal injection of lucentis for the treatment of wet age-related macular degeneration （AMD）. Methods Totally 77 pa- tients （77 eyes） with wet AMD were randomly divided into 2 groups： a combined treatment group （39 eyes） and a lucentis group （38 eyes）. The combined treatment group was treated with Sanxue Mingmu tablets combined with intravitreal injection of lucentis. The lucentis group was treated with intravitreal injection of lucentis alone. Intravit- real injection was once a month, 3 times in a row. Sanxue Mingmu tablets were taken orally for 3 months. We examined the best corrected visual acuity, optical correlation tomography （OCT） and fluorescence angiography （FFA） to know the changes of best corrected visual acuity, thickness of the retina in the macula and leakage of the retina. Results The best corrected visual acuity of the combined treatment group （0.09±0.05 vs 0.38±0.14） and the lu- centis group （0.08±0.04 vs 0.29±0.15） was improved. The difference between pre-treatment and post-treatment and that between the 2 groups were significant （P 〈 0.01 or P 〈 0.05）. Thickness of the retina in the macula of the combined treatment group [（315.44±21.99）μm vs （237.13±27.14）μm] and the lucentis group [（317.33±21.63）μm vs （254.56±26.32）μm] was decreased. After treatment for 3 months, The difference between pre-treatment and post-treatment and that between the 2 groups were significant （P 〈 0.01 or P 〈 0.05）. The leakage of the retina in the combined treatment group： the leakage in 28 eyes disappeared, significantly reduced in 7 and in the other 4 did not obvious change. In the lucentis group： the leakage in 24 eyes disappeared, significantly reduced in 3 and 11 had no significant change. After 3 month treatment, the difference between the combined treatment group and the lucentis group was significant （P 〈 0.05）. Conclusion Sanxue Mingmu tablets combined with intravitreal injection of lucentis are effective for wet AMD improving the visual acuity, reducing macula edema and the leakage of the retina.
出处
《中南药学》
CAS
2016年第3期329-332,共4页
Central South Pharmacy
关键词
散血明目片
雷珠单抗
眼内注射
湿性年龄相关性黄斑变性
Sanxue Mingmu tablet
lucentis
intravitreal injection
wet age-related macular degeneration
